Johnson & Johnson Will Likely See A Decline In Sales In 2019 Amid Generic Competition

Johnson & Johnson (NYSE:JNJ) recently posted its Q4 results, which were slightly below our estimates. The company saw 1% revenue growth and a 13% jump in adjusted earnings to $1.97 per share. While the Pharmaceuticals segment saw 5% revenue gains led by oncology drugs, the Medical Devices segment...